Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 14

1.

New and repurposed drugs to treat multidrug- and extensively drug-resistant tuberculosis.

Silva DR, Dalcolmo M, Tiberi S, Arbex MA, Munoz-Torrico M, Duarte R, D'Ambrosio L, Visca D, Rendon A, Gaga M, Zumla A, Migliori GB.

J Bras Pneumol. 2018 Apr;44(2):153-160. doi: 10.1590/s1806-37562017000000436. Portuguese, English.

2.

Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs.

Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, Arbex MA, Augusto VM, Rabahi MF, Mello FCQ.

J Bras Pneumol. 2018 Apr;44(2):145-152. doi: 10.1590/s1806-37562017000000443. Portuguese, English.

3.

Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico.

Munoz-Torrico M, Salazar MA, Millán MJM, Martínez Orozco JA, Narvaez Diaz LA, Segura Del Pilar M, Visca D, D'Ambrosio L, Centis R, Migliori GB.

Eur Respir J. 2018 Mar 22;51(3). pii: 1702267. doi: 10.1183/13993003.02267-2017. Print 2018 Mar. No abstract available.

PMID:
29567721
4.

New drugs and perspectives for new anti-tuberculosis regimens.

Tiberi S, Muñoz-Torrico M, Duarte R, Dalcolmo M, D'Ambrosio L, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):86-98. doi: 10.1016/j.rppnen.2017.10.009. Epub 2018 Feb 24.

5.

Tuberculosis, social determinants and co-morbidities (including HIV).

Duarte R, Lönnroth K, Carvalho C, Lima F, Carvalho ACC, Muñoz-Torrico M, Centis R.

Pulmonology. 2018 Mar - Apr;24(2):115-119. doi: 10.1016/j.rppnen.2017.11.003. Epub 2017 Dec 21.

6.

Team approach to manage difficult-to-treat TB cases: Experiences in Europe and beyond.

D'Ambrosio L, Bothamley G, Caminero Luna JA, Duarte R, Guglielmetti L, Muñoz Torrico M, Payen MC, Saavedra Herrera N, Salazar Lezama MA, Skrahina A, Tadolini M, Tiberi S, Veziris N, Migliori GB.

Pulmonology. 2018 Mar - Apr;24(2):132-141. doi: 10.1016/j.rppnen.2017.10.005. Epub 2017 Dec 8.

7.

Interleukin-17 limits hypoxia-inducible factor 1α and development of hypoxic granulomas during tuberculosis.

Domingo-Gonzalez R, Das S, Griffiths KL, Ahmed M, Bambouskova M, Gopal R, Gondi S, Muñoz-Torrico M, Salazar-Lezama MA, Cruz-Lagunas A, Jiménez-Álvarez L, Ramirez-Martinez G, Espinosa-Soto R, Sultana T, Lyons-Weiler J, Reinhart TA, Arcos J, de la Luz Garcia-Hernandez M, Mastrangelo MA, Al-Hammadi N, Townsend R, Balada-Llasat JM, Torrelles JB, Kaplan G, Horne W, Kolls JK, Artyomov MN, Rangel-Moreno J, Zúñiga J, Khader SA.

JCI Insight. 2017 Oct 5;2(19). pii: 92973. doi: 10.1172/jci.insight.92973. [Epub ahead of print]

8.

Novel role for IL-22 in protection during chronic Mycobacterium tuberculosis HN878 infection.

Treerat P, Prince O, Cruz-Lagunas A, Muñoz-Torrico M, Salazar-Lezama MA, Selman M, Fallert-Junecko B, Reinhardt TA, Alcorn JF, Kaushal D, Zuñiga J, Rangel-Moreno J, Kolls JK, Khader SA.

Mucosal Immunol. 2017 Jul;10(4):1069-1081. doi: 10.1038/mi.2017.15. Epub 2017 Mar 1.

9.

Diabetes is Associated with Severe Adverse Events in Multidrug-Resistant Tuberculosis.

Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Vergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Arch Bronconeumol. 2017 May;53(5):245-250. doi: 10.1016/j.arbres.2016.10.021. Epub 2017 Jan 11. English, Spanish.

10.

Comparison of bacteriological conversion and treatment outcomes among MDR-TB patients with and without diabetes in Mexico: Preliminary data.

Muñoz-Torrico M, Caminero Luna J, Migliori GB, D'Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, Torres-Cruz A, Flores-Ergara H, Martínez-Mendoza D, García-Sancho C, Centis R, Salazar-Lezama MÁ, Pérez-Padilla R.

Rev Port Pneumol (2006). 2017 Jan - Feb;23(1):27-30. doi: 10.1016/j.rppnen.2016.11.009. Epub 2016 Dec 31.

11.

Classifying new anti-tuberculosis drugs: rationale and future perspectives.

Tiberi S, Scardigli A, Centis R, D'Ambrosio L, Muñoz-Torrico M, Salazar-Lezama MÁ, Spanevello A, Visca D, Zumla A, Migliori GB, Caminero Luna JA.

Int J Infect Dis. 2017 Mar;56:181-184. doi: 10.1016/j.ijid.2016.10.026. Epub 2016 Nov 3.

12.

Is there a rationale for pulmonary rehabilitation following successful chemotherapy for tuberculosis?

Muñoz-Torrico M, Rendon A, Centis R, D'Ambrosio L, Fuentes Z, Torres-Duque C, Mello F, Dalcolmo M, Pérez-Padilla R, Spanevello A, Migliori GB.

J Bras Pneumol. 2016 Sep-Oct;42(5):374-385. doi: 10.1590/S1806-37562016000000226. Review. English, Portuguese.

13.

Humoral and cellular responses to a non-adjuvanted monovalent H1N1 pandemic influenza vaccine in hospital employees.

Herrera MT, Gonzalez Y, Juárez E, Hernández-Sánchez F, Carranza C, Sarabia C, Guzman-Beltran S, Manjarrez ME, Muñoz-Torrico M, Garcia-Garcia L, Sada E, Torres M.

BMC Infect Dis. 2013 Nov 15;13:544. doi: 10.1186/1471-2334-13-544.

14.

[The response of the intensive care units during the influenza A H1N1 pandemic: the experience in Chiapas, Mexico].

Volkow P, Bautista E, de la Rosa M, Manzano G, Muñoz-Torrico MV, Pérez-Padilla R.

Salud Publica Mex. 2011 Jul-Aug;53(4):345-53. Spanish.

Supplemental Content

Loading ...
Support Center